It has also been shown that plasma VEGF-A concentrations are associated with the development of hypertension after angiogenesis inhibitor used, with increased plasma levels of VEGF-A observed in treatment with VEGF pathway inhibitor and with insufficient NO production by endothelial cells to cause adequate vasodilation in a subgroup of patients with low VEGF-A levels, and that treatment with bevacizumab in these patients may further limit NO release from endothelial cells and other vasodilators, leading to severe hypertension after treatment. The gene discussed is VEGFA; the disease is Hypertension.